원발개방각녹내장 및 고안압증 환자에서 오미데네팍이소프로필 0.002%의 단기간 효과와 안전성
Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 원발개방각녹내장 및 고안압증 환자에서 오미데네팍이소프로필 0.002% 제제의 단기간 효과와 안전성을 분석하였다. 대상과 방법: 2021년 1월부터 2022년 5월까지 원발개방각녹내장과 고안압증으로 진단된 36명 36안을 대상으로 후향적 연구를 진행하였다. 오미데네팍이소프로필 0.002% 제제를 사용한 후 1개월, 3개월 후의 안압하강 효과를 분석하였으며 매 방문 시마다 환자들의부작용을 조사하였다. 결과: 치료 시작 시점의 환자들의 평균 나이는 59.2세였다. 36명의 환자 중 33명은 원발개방각녹내장, 3명은 고안압증으로 진단받았다. 치료 시작 전 기저 안압은 15.9 ± 3.6 mmHg였으며, 이는 오미데네팍이소프로필 0.002% 제제 투여 후 1개월과 3개월 후 각각13.7 ± 2.8 mmHg, 13.4 ± 2.9 mmHg로 유의미하게 감소하였다(p<0.01). 12명의 환자들이 결막충혈, 안구통증, 가려움을 포함하는부작용을 호소하였으나 부작용으로 인하여 사용을 중지한 경우는 2명(5.5%)이었다. 결론: 원발개방각녹내장과 고안압증 환자에서 오미데네팍이소프로필 0.002% 제제의 단기간 안압하강 효과와 안전성을 확인할 수있었다.
Abstract
Purpose: To analyze the short-term efficacy and safety of omidenepag isopropyl 0.002% (w/v) in patients with primary open-angle glaucoma and ocular hypertension. Methods: Data on 36 patients with primary open-angle glaucoma and ocular hypertension treated with omidenepag isopropyl 0.002% (w/v) from January 2021 to May 2022 were retrospectively analyzed. We investigated whether the drug lowered the intraocular pressure (IOP) at 1 and 3 months compared to baseline. Possible side effects were sought at each visit. Results: The mean patient age was 59.2 years at the time of treatment. Of the 36 patients, 33 had primary open-angle glaucoma and 3 had ocular hypertension. The baseline IOP was 15.9 ± 3.6 mmHg, which significantly decreased to 13.7 ± 2.8 and 13.4 ± 2.9 mmHg at 1 and 3 months, respectively, following instillation of omidenepag isopropyl 0.002% (w/v) (both p < 0.01). Twelve patients (29.2%) experienced side effects including hyperemia, ocular pain, and itching but only two (5.5%) stopped using the medication. Conclusions: In the short-term, ominedepag isopropyl 0.002% (w/v) is effective and safe in patients with primary open-angle glaucoma and ocular hypertension.
참고문헌 (17)
- Weinreb RN, "The pathophysiology and treatment of glaucoma : a review", JAMA, 311, pp.1901~1911 (2014)
- European Glaucoma Society, "European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th edition-chapter 3 : treatment principles and options", Br J Ophthalmol, 101, pp.130~195 (2017)
- Prum BE Jr, "Primary open-angle glaucoma preferred practice pattern ®guidelines", Ophthalmology, 123, pp.41~111 (2016)
- Inoue K, "Adverse periocular reactions to five types of prostaglandin analogs", Eye(Lond), 26, pp.1465~1472 (2012)
- Inoue K, "Nonresponders to prostaglandin analogs among normal-tension glaucoma patients", J Ocul Pharmacol Ther, 32, pp.90~96 (2016)
- Matsuo M, "Efficacy and patient tolerability of omidenepag isopropyl in the treatment of glaucoma and ocular hypertension", Clin Ohthalmol, 16, pp.1261~1279 (2022)
- Fuwa M, "Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys", J Ocul Pharmacol Ther, 34, pp.531~537 (2018)
- Nilsson SF, "The prostanoid EP2receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey", Invest Ophthalmol Vis Sci, 47, pp.4042~4049 (2006)
- Schlötzer-Schrehardt U, "Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues", Invest Ophthalmol Vis Sci, 43, pp.1475~1487 (2002)
- Inoue K, "One-year efficacy and safety of omidenepag isopropyl in patients with normaltension glaucoma", J Ocul Pharmacol Ther, 38, pp.354~358 (2022)
- Aihara M, "Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension", J Glaucoma, 28, pp.375~385 (2019)
- Aihara M, "Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension : the phase 3 AYAME study", Am J Ophthalmol, 220, pp.53~63 (2020)
- Alm A, "Side effects associated with prostaglandin analog therapy", Surv Ophthalmol, 53(Suppl 1), pp.S93~S105 (2008)
- "LUMIGAN_0.01% and 0.03% prescribing information" (2017)[URL]
- "TRAVATAN Z_prescribing information" (2017)[URL]
- Lee SH, "Influence of 0.002% omidenepag isopropyl on intraocular pressure and the cornea in normal tension glaucoma", J Glaucoma, 32, pp.245~251 (2023)
- Manju M, "Prostaglandin-associated periorbitopathy : a prospective study in Indian eyes", Kerala J Ophthalmol, 32, pp.36~40 (2020)